Lion Biotechnologies Inc., of Los Angeles, said researchers from Moffitt Cancer Center reported results from a pilot trial of tumor infiltrating lymphocytes (TIL) and Yervoy (ipilimumab, Bristol-Myers Squibb Co.) in patients with metastatic melanoma at the Society of Surgical Oncology 2015 meeting in Houston.